Peptide Health Lab

Goal

Recovery

Also known as: Injury recovery, Tissue repair

A research reference for the peptides mapped to injury recovery and tissue repair, covering what the animal literature established, what the handful of human trials actually measured, and how to tell the two apart.

Last reviewed August 3, 2026

What "recovery" actually means in the research

Recovery is a word people bring to a search engine. It is not a word that appears in the studies underneath these compounds, and the difference is the single most useful thing this page can tell you.

The literature does not study recovery. It studies a rat Achilles tendon sharply detached from the calcaneus, an injury that does not heal on its own.[2] It studies a dystrophin-deficient mouse exercised twice a week for six months.[5] It studies an open venous stasis ulcer on a human leg.[6] It studies a serum IGF-1 concentration in a healthy adult volunteer who was not injured at all.[3]

Four models, four different questions, and none of them is the question most readers actually have: whether a hamstring strain will heal faster, whether a shoulder will stop aching, whether the next training block will feel easier than the last one. A narrative review of peptides in sports medicine makes the same point from the clinical side: patient demand for accelerated injury recovery has grown much faster than the evidence base under it, and a parallel market of unapproved compounds has grown to meet the demand.[13]

So the first job of this page is translation. Everything below is organized around which question a given piece of evidence actually answered.

What the evidence supports

Tendon and connective tissue, in rodents. This is the strongest signal in the whole area. In rats whose Achilles tendon was transected from the bone, daily intraperitoneal BPC-157 improved functional index scores, load to failure, stiffness, and collagen organization, and reduced the healing impairment caused by concurrent corticosteroid.[2] Reviews of musculoskeletal soft-tissue healing treat this and the related cell work as a coherent, reproducible preclinical finding.[10]

Muscle fibre regeneration, in mice, without a functional change. Six months of thymosin β4 in exercised dystrophic mice significantly increased the number of regenerating skeletal muscle fibres, and the peptide localized specifically to those fibres. In the same animals, grip strength, systolic cardiac function, and fibrosis were not significantly better than in untreated controls.[5] Both halves of that result belong on this page.

Wound healing in humans, but for a different molecule. Thymosin β4, the full-length 43-amino-acid protein, has been through real randomized human work. A double-blind, placebo-controlled dose-escalation study across eight European sites randomized 73 patients with venous stasis ulcers to a topical formulation, found the safety profile comparable to placebo, and reported that one dose level suggested accelerated healing.[6] An intravenous single- and multiple-dose randomized study in healthy volunteers found it tolerated across a wide dose range without dose-limiting toxicity.[7] The regenerative properties of the parent protein are well characterized.[8] TB-500 is a short fragment of that protein. It was not the molecule in those trials, and no published study has compared the two head to head.

Growth hormone and IGF-1, in humans. Randomized, placebo-controlled ascending-dose trials of CJC-1295 in healthy adults produced dose-dependent increases in plasma growth hormone of two- to ten-fold lasting six days or more, and in IGF-1 of 1.5- to three-fold lasting nine to eleven days.[3] Ipamorelin produced a single episode of growth hormone release at every infusion rate tested in healthy male volunteers.[1] These are real, well-conducted human pharmacology studies. They measured hormone concentrations.

Where the evidence is weak

No human trial has measured recovery. Not one of these compounds has been tested against a healing, function, or return-to-play endpoint in a published randomized controlled trial. The only human report of a repair outcome anywhere on this page is a retrospective single-clinic chart review in which sixteen patients who had received intra-articular BPC-157 were surveyed by telephone about their knee pain, with no control group, no randomization, no standardized instrument, and no imaging follow-up.[11] Independent review states the position directly: these compounds are not approved because no clinical studies confirming human benefit exist.[12]

The one randomized human efficacy trial on this page failed. Ipamorelin was tested in 114 patients undergoing bowel resection in a multicentre, double-blind, placebo-controlled trial of postoperative ileus. It was well tolerated, and there were no significant differences from placebo on the key or secondary efficacy endpoints.[9] A negative trial is information, and it is the most rigorous human efficacy information any compound here has produced.

The surrogate has been tested and does not carry. If elevated growth hormone were sufficient, growth hormone itself would work. It has been given to healthy, fit young adults across 27 randomized study samples and pooled: lean body mass increased by roughly two kilograms, strength did not appear to improve, exercise capacity may have worsened, and soft-tissue edema and fatigue were more frequent.[4] Anything that argues from "it raises growth hormone" to "it speeds recovery" has to get past that result first.

Four weak evidence bases do not sum to a strong one. Mapping four compounds to one goal can create an impression of convergence that the underlying studies do not support. They converge on a mechanism story, not on an outcome. The sports-medicine review covering this exact set treats placebo response, amplified by social media, as a genuine mediator of their apparent efficacy.[13]

Long-term safety is unstudied. The animal work was designed to detect healing effects over weeks. Nothing in the published record addresses years of exposure in a healthy person using these compounds for training recovery.[12]

How to decide between these

The decision framework below the compound cards is the short version; the principle behind it is that the right comparison is almost never between two peptides. It is between a peptide with animal-only evidence and a standard-of-care option with human evidence for the specific injury in question.

Three filters do most of the work. First, name the injury. If there isn't one, and what you mean is training fatigue, nothing on this page has been studied for that in any species.[5] Second, decide what counts as evidence for you, because applying "published human efficacy data" as a filter empties this page almost completely.[11] Third, if you compete under anti-doping rules, stop at the section below; nothing after it applies.

The stack assessment on this site is built to structure that conversation rather than to answer it, and its output is a starting point for a provider visit, not a protocol.

Questions to bring to a provider

The productive version of this conversation is not "should I try BPC-157." It is "here is the injury, here is what I want back, what has actually been shown to get me there."

  • What is the working diagnosis, and what does the standard-of-care evidence offer for it specifically?
  • Given that the tendon evidence is entirely rodent and cell work, what would have to be true for an unapproved peptide to be worth considering at all?[10]
  • If the proposal rests on raising growth hormone, how should the pooled finding that growth hormone does not improve strength or exercise capacity change the reasoning?[4]
  • Does a personal or family history of malignancy change the calculus, given that angiogenesis and IGF-1 signalling are the central proposed mechanisms?[12]
  • Which objective measure would show whether anything changed, rather than relying on how it feels: imaging, load testing, or a validated function score?
  • If competing in a tested sport, what does this year's prohibited list say?

Anti-doping status

Every compound mapped on this page is prohibited in tested sport at all times, both in and out of competition, under the World Anti-Doping Agency Prohibited List in force for 2026:

  • BPC-157: section S0, non-approved substances. S0 covers any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use, and BPC-157 is named in it as an example. Substances in this class are Specified Substances.
  • TB-500: section S2.3, growth factors and growth factor modulators. The list names "thymosin-β4 and its derivatives" and gives TB-500 as the example.
  • CJC-1295: section S2.2.4, growth hormone releasing factors, under GHRH and its analogues.
  • Ipamorelin: section S2.2.4, under growth hormone secretagogues and their mimetics.

Substances in the S2 class are non-Specified Substances, which carries different sanctioning consequences from S0. That distinction is worth raising with a national anti-doping organization rather than settling from a web page.

Two cautions about this section specifically. First, the status above is read from the published Prohibited List itself rather than from the research literature, because the research literature has carried it wrongly: a 2025 review of BPC-157 states that its 2022 ban was temporary and that it is not currently listed, and that parenthetical is the origin of a claim that still circulates widely.[12] The review remains a reasonable survey of the preclinical work; it is not a source for anti-doping status, and neither is any other review.[13] Second, the list is reissued every year and sections renumber. A competing athlete should confirm the current year's list rather than this page.

What the evidence supports for this goal

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Tendon and ligament healing
Animal studies only animal · review

In rats whose Achilles tendon was sharply detached from the calcaneus, daily intraperitoneal BPC-157 improved functional index scores, load to failure, stiffness, and collagen organization. Reviews of musculoskeletal soft-tissue healing treat this as the strongest signal in the field and also state plainly that it has never been tested in a human trial.

[2] [10]

Skeletal muscle repair
Animal studies only animal · review

Chronic thymosin β4 in exercised dystrophin-deficient mice increased the number of regenerating skeletal muscle fibres over six months. It did not significantly improve grip strength, systolic cardiac function, or fibrosis compared with untreated animals. A histological change without a functional change is the honest summary of the muscle evidence.

[5] [8]

Wound healing with full-length thymosin β4 in humans
Human RCT evidence human RCT · review

A double-blind, placebo-controlled, dose-escalation study across eight European sites randomized 73 patients with venous stasis ulcers to topical thymosin β4; the authors report the safety profile as comparable to placebo and describe the efficacy findings as suggesting that one dose level may accelerate healing. A separate randomized single- and multiple-dose intravenous study in 40 healthy volunteers found it tolerated with no dose-limiting toxicity, and measured pharmacokinetics rather than repair. Both studied the full 43-amino-acid protein in a pharmaceutical formulation. TB-500 is a seven-residue fragment and was not the molecule in either trial.

[6] [7] [8]

Raising growth hormone and IGF-1 in humans
Human RCT evidence human RCT · human observational

This is the best-established human claim on the page, and it is a surrogate. Randomized placebo-controlled ascending-dose trials of CJC-1295 in healthy adults produced dose-dependent increases in growth hormone of two- to ten-fold and in IGF-1 of 1.5- to three-fold lasting days, and ipamorelin produced a single episode of growth hormone release across every infusion rate tested in healthy male volunteers. Neither programme measured healing, recovery, or any tissue outcome.

[3] [1]

Recovery, healing, or return-to-play outcomes in humans
Anecdotal reports only human observational · human RCT · review

No published randomized controlled trial has tested any of these compounds against a recovery, healing, or return-to-play endpoint in humans. The only human repair report is a retrospective single-clinic chart review in which sixteen patients were surveyed by telephone about knee pain. The one randomized human efficacy trial of ipamorelin, in postoperative ileus, found no significant difference from placebo on its key endpoint. Reviews of the field state the absence of human efficacy data directly.

[11] [9] [12] [13]

Compounds people map to this goal

Each card carries the compound's FDA status and its overall evidence grade, plus why it shows up on this goal in particular. Follow the card to the full library page for the claim-by-claim evidence review and what published research reported. Dosing and protocol ranges are never on this page.

FOR RESEARCH PURPOSES ONLY

BPC-157

Also known as: Body Protection Compound 157, PL 14736, PLD-116

Research only Animal studies only

A research reference for BPC-157, a pentadecapeptide with a large rodent literature on tissue repair and gut protection and almost no human evidence.

Why it's on this page

The compound most people arrive here looking for, and the one with the largest preclinical literature: rodent models of tendon, ligament, muscle, and gastrointestinal injury. It is also the only compound on this page with any published human report of a repair outcome, and that report is a sixteen-patient telephone survey. Prohibited in tested sport at all times under WADA section S0.

Last reviewed July 15, 2026

FOR RESEARCH PURPOSES ONLY

TB-500

Also known as: Thymosin Beta-4 fragment, TB4, N-acetylated LKKTETQ

Research only Animal studies only

A research reference for TB-500, a synthetic seven-amino-acid fragment of thymosin β4 that is routinely confused with the full protein whose clinical trials it did not participate in.

Why it's on this page

A seven-amino-acid fragment mapped here because the full-length protein it comes from, thymosin β4, has genuine randomized human wound-healing data behind it. The fragment itself did not generate that data and has never been compared against it. Named on the WADA list by name under section S2.3, prohibited at all times.

Last reviewed August 2, 2026

FOR RESEARCH PURPOSES ONLY

CJC-1295

Also known as: CJC-1295 with DAC, DAC:GRF, hGRF(1-29) albumin bioconjugate

Research only Anecdotal reports only

A research reference for CJC-1295, a long-acting GHRH analog with two small human pharmacology studies showing raised GH and IGF-1 and no trial of any clinical outcome.

Why it's on this page

A long-acting GHRH analogue, on this page because raising growth hormone and IGF-1 is the mechanism most often invoked for faster tissue repair. The hormone rise is real, dose-dependent, and measured in humans; the repair outcome is the part that has never been measured. Prohibited at all times under WADA section S2.2.4.

Last reviewed August 2, 2026

FOR RESEARCH PURPOSES ONLY

Ipamorelin

Research only Anecdotal reports only

A research reference for ipamorelin, a selective growth-hormone secretagogue with solid rodent pharmacology, one human dose-ranging study, and one phase 2 trial that missed its endpoint.

Why it's on this page

A selective growth-hormone secretagogue, almost always discussed alongside CJC-1295 for the same mechanism. Its one randomized controlled human efficacy trial was in postoperative ileus and did not separate from placebo. Prohibited at all times under WADA section S2.2.4.

Last reviewed August 2, 2026

How to decide between them

These are the questions that actually change the answer. Work through them with a licensed provider. None of them can be answered by a page that does not know your labs, your history, or your medications.

  1. Are you recovering from a diagnosed structural injury, or from training load?

    Every preclinical model behind these compounds is discrete tissue damage: a transected tendon, a dystrophic muscle, an open ulcer. Nothing in this literature models ordinary training soreness, accumulated fatigue, or between-session readiness. If that is what you mean by recovery, the honest answer is that no compound on this page has been studied for it in any species, and the question to take to a clinician is about sleep, load management, and nutrition instead.

    Animal studies only [2] [5]

  2. Are you asking for evidence in humans, or evidence in rats?

    Applying that filter empties most of this page. Filtering to compounds with a published human efficacy result for a tissue-repair endpoint leaves BPC-157's uncontrolled sixteen-patient chart review and thymosin β4's venous-ulcer programme. The second of those studied the full-length protein in a pharmaceutical topical formulation, not the fragment sold under the name TB-500. That is the entire human repair literature for this page.

    Anecdotal reports only [11] [6]

  3. Would a higher growth hormone and IGF-1 level actually settle it?

    CJC-1295 and ipamorelin have real human pharmacology behind them: both reliably raise growth hormone, and CJC-1295 raises IGF-1 for days. That is a surrogate endpoint, and the surrogate has been tested directly. When growth hormone itself was given to healthy, fit young adults across 27 randomized study samples, lean body mass rose, strength did not improve, exercise capacity did not improve, and soft-tissue edema and fatigue became more common. Raising the hormone is not the same as recovering faster.

    Human RCT evidence [3] [4]

  4. Do you compete in a tested sport, at any level?

    Then the decision is already made and no evidence question follows it. All four compounds mapped on this page are prohibited at all times, in and out of competition, under the WADA Prohibited List in force for 2026: BPC-157 under S0, TB-500 under S2.3, CJC-1295 and ipamorelin under S2.2.4. That is read from the published list itself, not from the research literature, because published reviews have stated it wrongly. Confirm the current year's list rather than this page.

    [13]

  5. How would you know afterwards whether anything actually worked?

    Recovery is the domain where natural healing time and expectation are hardest to separate from an intervention, and the sports-medicine review covering these compounds treats placebo response, amplified by social media, as a genuine mediator of their apparent effect. Deciding in advance on something objective, such as imaging, a validated function score, or a measured strength benchmark, is what separates a decision from a story told afterwards.

    [13]

Questions for your provider

Bring this goal page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here applies to your situation. This goal page cannot. Peptide Health Lab does not prescribe and does not sell peptides.

A goal is not a diagnosis. The most useful version of this conversation usually starts with what is actually driving the symptom, not with which compound to try.

Citations

13 sources · every identifier checked against PubMed

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Want a structured starting point for that conversation?

Open the Stack Builder